Editorial: IEEE Transactions on Human-Machine Systems: Year in Review for 2013

E. Bass

DOI: https://doi.org/10.1109/thms.2014.2298286

Abstract:

What problem does this paper attempt to address?

Progress in Sodium-glucose Co-transporter-2 Inhibitors: the New Target for Treatment of Type 2 Diabetes

徐鸽,沈玫,吕彬华,许百华,李绍顺

2009-01-01

Abstract:Sodium-glucose co-transporters(SGLT) are a family of glucose transporter found in the intestinal mucosa of the small intestine(SGLT) and the proximal tubule of the nephron(SGLT2 and SGLT1).They contribute to renal glucose reabsorption.The sodium-glucose co-transporter-2(SGLT2) is a low-affinity transport system that is specifically expressed in the kidney and play a very important role in renal glucose reabsorption in the proximal tubule.Selective inhibition of SGLT2 is an innovative therapeutic strategy for treatment of type 2 diabetes patients by enhancing glucose loss through the urine.In this paper,the latest research progress on SGLT2 inhibitors for the treatment of type 2 diabetes were introduced.We emphasized the mechanism of SGLT2 inhibitors,the data of biological activities and clinical trials of some SGLT2 inhibitors under research and development.
SGLT2i: beyond the glucose-lowering effect

Lihua Ni,Cheng Yuan,Guopeng Chen,Changjiang Zhang,Xiaoyan Wu

DOI: https://doi.org/10.1186/s12933-020-01071-y

IF: 8.949

2020-06-26

Cardiovascular Diabetology

Abstract:Sodium/glucose cotransporter-2 inhibitors (SGLT2i) are a new type of glucose-lowering drug that can reduce blood glucose by inhibiting its reabsorption in proximal tubules and by promoting urinary glucose excretion. SGLT2i are widely used in the clinical treatment of type 2 diabetes mellitus (T2DM). In recent studies, SGLT2i were found to not only reduce blood glucose but also protect the heart and kidney, which can significantly reduce cardiovascular events, delay the progression of renal failure, greatly improve the quality of life of patients, and reduce medical expenses for families and society. As adverse cardiac and renal events are the most common and serious complications of T2DM, it is very important to understand the cardio- and renoprotective mechanisms of SGLT2i. This article reviews the historical development, pharmacological mechanism, heart and kidney protection and safety of SGLT2i. The information presented provides a theoretical basis for the clinical prevention and treatment of diabetes and its complications and for the development of new glucose-lowering drugs.

cardiac & cardiovascular systems,endocrinology & metabolism
SGLT2 inhibitors for the treatment of diabetes: a patent review (2019-23)

Rahul Baghel,Nikita Chhikara,Pawan Kumar,Akhilesh Kumar Tamrakar

DOI: https://doi.org/10.1080/13543776.2024.2379929

Abstract:Introduction: The sodium-glucose co-transporter 2 (SGLT2) inhibitors are FDA-approved class of drugs for diabetes management. They improve glycemic control by inducing glucosuria. Notwithstanding with potent anti-hyperglycemic activity, SGLT2 inhibitors are emerging as drugs with multifaceted therapeutic potential, evidenced for cardioprotective, renoprotective, antihypertensive, and neuroprotective activities. Continuous attempts are being accomplished through structural modification, development of new formulation, or combination with other drugs, to enhance the bioactivity spectrum of SGLT2 inhibitors for better management of diabetes and related complications. Areas covered: This review comprises a summary of patent applications, acquired using the Espacenet Patent Search database, concerning SGLT2 inhibitors from 2019 to 2023, with focus on improving therapeutic potentials in management of diabetes and metabolic complications. Expert opinion: SGLT2 inhibitors have provided an exciting treatment option for diabetes. Originally developed as anti-hyperglycemic agents, SGLT2 inhibitors exert pleiotropic metabolic responses and have emerged as promising antidiabetic agents with cardio-protective and reno-protective activities. Given their distinct therapeutic profile, SGLT2 inhibitors have revolutionized the management of diabetes and associated complications. Emerging evidences on their therapeutic potential against cancer, male reproductive dysfunctions, and neurodegenerative diseases indicate that further research in this field may unfold novel prospective on their plausible use in the management of other chronic conditions.
Synthetic approaches and clinical application of small-molecule inhibitors of sodium-dependent glucose transporters 2 for the treatment of type 2 diabetes mellitus

Tong Xie,Li-Jie Zhao

DOI: https://doi.org/10.1016/j.ejmech.2024.116343

IF: 7.088

2024-03-21

European Journal of Medicinal Chemistry

Abstract:Sodium-dependent glucose transporters 2 (SGLT2) inhibitors are a class of small-molecule drugs that have gained significant attention in recent years for their potential clinical applications in the treatment of type 2 diabetes mellitus (T2DM). These inhibitors function by obstructing the kidneys' ability to reabsorb glucose, resulting in a rise in the excretion of glucose in urine (UGE) and subsequently lowering blood glucose levels. Several SGLT2 inhibitors, such as Dapagliflozin, Canagliflozin, and Empagliflozin, have been approved by regulatory authorities and are currently available for clinical use. These inhibitors have shown notable enhancements in managing blood sugar levels, reducing body weight, and lowering blood pressure in individuals with T2DM. Additionally, they have exhibited potential advantages in decreasing the likelihood of cardiovascular incidents and renal complications among this group of patients. This review article focuses on the synthesis and clinical application of small-molecule SGLT2 inhibitors, which have provided a new therapeutic approach for the management of T2DM.

chemistry, medicinal
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Nondiabetic Patients with Chronic Kidney Disease: A Review of Recent Evidence

Junhao Lv,Luying Guo,Rending Wang,Jianghua Chen

DOI: https://doi.org/10.1159/000530395

2023-01-01

Kidney Diseases

Abstract:Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) were initially developed as glucose-lowering agents in patients with type-2 diabetes. However, available data from clinical trials and meta-analyses suggest that SGLT2i have pleiotropic benefits in reducing mortality and delaying the progression of chronic kidney disease (CKD) in both diabetic and nondiabetic patients. Thus, we herein review the current evidence regarding the efficacy and safety of SGLT2i in patients with nondiabetic CKD and appraise the recently reported clinical trials that might facilitate the management of CKD in routine clinical practice. Summary: The benefits of SGLT2i on nondiabetic CKD are multifactorial and are mediated by a combination of mechanisms. The landmark DAPA-CKD trial revealed that dapagliflozin administered with renin-angiotensin system blockade drugs reduced the risk of a sustained decline (at least 50%) in the estimated glomerular filtration rate, end-stage kidney disease, or death from cardiorenal causes. The recent EMPA-KIDNEY trial showed that empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes. These benefits were consistent in patients with and without diabetes. Moreover, a meta-analysis of DAPA-HF and EMPEROR-Reduced trials confirmed reductions in the combined risk of cardiovascular death or worsening heart failure including composite renal endpoint. Key Messages: Considering the robust data available from DAPA-CKD, EMPA-KIDNEY, and other trials such as EMPEROR-Preserved, DIAMOND that included nondiabetic patients, it may be necessary to update current guidelines to include SGLT2i as a first-line therapy for CKD and reevaluate current CKD therapeutic approaches.
Sodium-glucose Cotransporter Type 2 Inhibitors: A New Insight into the Molecular Mechanisms of Diabetic Nephropathy.

Na Li,Hong Zhou

DOI: https://doi.org/10.2174/1381612828666220617153331

IF: 3.31

2022-06-23

Current Pharmaceutical Design

Abstract:Diabetic nephropathy is one of the chronic microvascular complications of diabetes and is a leading cause of end-stage renal disease. Fortunately, clinical trials have demonstrated that sodium–glucose cotransporter type 2 inhibitors could decrease proteinuria and improve renal endpoints and are promising agents for the treatment of diabetic nephropathy. The renoprotective effects of sodium–glucose cotransporter type 2 inhibitors cannot be simply attributed to their advantages in aspects of metabolic benefits, such as glycemic control, lowering blood pressure, and control of serum uric acid, or improving hemodynamics associated with decreased glomerular filtration pressure. Some preclinical evidence suggests that sodium–glucose cotransporter type 2 inhibitors exert their renoprotective effects by multiple mechanisms, including attenuation of oxidative and endoplasmic reticulum stresses, anti-fibrosis and anti-inflammation, protection of podocytes, suppression of megalin function, improvement of renal hypoxia, restored mitochondrial dysfunction and autophagy, as well as inhibition of sodium-hydrogen exchanger 3. In the present study, the detailed molecular mechanisms of sodium–glucose cotransporter type 2 inhibitors with the actions of diabetic nephropathy were reviewed, with the purpose of providing the basis for drug selection for the treatment of diabetic nephropathy Keywords: Sodium glucose cotransporter 2 inhibitors, Diabetic nephropathy, Renal protection, Molecular mechanism, Renal hypoxia, Podocyte protection.

pharmacology & pharmacy
SGLT2-INHIBITORS: A NOVEL CLASS FOR THE TREATMENT OF TYPE 2 DIABETES INTRODUCTION OF SGLT2-INHIBITORS IN CLINICAL PRACTICE

J Cuypers,C Mathieu,K Benhalima

DOI: https://doi.org/10.2143/acb.3349

2013-07-01

Acta Clinica Belgica

Abstract:Treatment of type 2 diabetes (T2DM) continues to present challenges, with significant proportion of patients failing to achieve and maintain glycemic targets. Despite the availability of many oral antidiabetic agents, therapeutic efficacy is offset by side effects such as weight gain and hypoglycemia. Therefore, the search for novel therapeutic agents with an improved benefit-risk profile continues. Recent research has focused on the kidney as a potential therapeutic target, especially because maximal renal glucose reabsorption is increased in T2DM. Under normal physiological conditions, nearly all filtered glucose is reabsorbed in the proximal tubule of the nephron, principally via the sodium-glucose cotransporter 2 (SGLT2). SGLT2-inhibitors are a new class of oral antidiabetics, which reduce hyperglycemia by increasing urinary glucose excretion independently of insulin secretion or action. Clinical results are promising with significant lowering of HbA1c without increased risk of hypoglycemia, reduction of body weight and reduction of systolic blood pressure. Dapagliflozin is the first highly selective SGLT2-inhibitor approved by the European Medecine Agency. Canagliflozin and empagliflozin are undergoing phase III trials. Actual safety issues are an increased risk for genital- and urinary tract infections and a possible increased risk for bladder and breast cancer. This led to refusal of dapagliflozin by the Food and Drug Administration (FDA). A large randomized control trial is therefore warranted by the FDA. This review provides an overview of the current evidence available so far on the therapeutic potential of the SGLT2-inhibitors for the treatment of T2DM.

medicine, general & internal
An apprise on novel drug delivery systems for management of diabetes mellitus

Ekta Pardhi,Yojana Bhor,Pankaj Kumar Singh,Neelesh Kumar Mehra

DOI: https://doi.org/10.1016/j.jddst.2024.105473

IF: 5

2024-02-24

Journal of Drug Delivery Science and Technology

Abstract:In the context of therapeutics for Type 2 Diabetes Mellitus, challenges emerge when conventional strategies, including diet and exercise, fall short of adequately controlling hyperglycemia. Despite the initial effectiveness observed in pharmacological interventions, they are burdened by notable limitations primarily arising from low bioavailability and immediate drug release. This necessitates an increased dosing frequency. The compounded impact of these constraints and the manifestation of adverse side effects significantly impede patient adherence to prescribed treatment regimens. In response to these challenges, recent years have witnessed a growing application of nanotechnology to devise innovative delivery modalities to enhance anti-diabetic approaches' effectiveness. The central objectives have centered on protecting the drug through encapsulation within nano-carrier systems and facilitating a gradual, controllable release. However, despite the proliferation of studies in this domain, there is a notable scarcity of research utilizing in vivo techniques in mouse/rat models to validate and substantiate findings. This review critically assesses the current disadvantages associated with contemporary Type 2 DM drugs and delves into the advancements made in nanotechnology. The emergence of drug nanocarriers can amplify bioavailability, prolong release durations, and consequently reduce dosing frequency. This innovative approach stands poised to significantly improve the quality of life for individuals grappling with Type 2 DM. Graphical abstract Download : Download high-res image (207KB) Download : Download full-size image

pharmacology & pharmacy
Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action

Yoshihito Fujita,Nobuya Inagaki

DOI: https://doi.org/10.1111/jdi.12214

2014-04-02

Journal of Diabetes Investigation

Abstract:Type 2 diabetes is characterized by impaired insulin secretion from pancreatic β-cells and/or reduced response of target tissues to insulin. Good glycemic control delays the development and slows the progression of micro- and macrovascular complications. Although there are numerous glucose-lowering agents in clinical use, only approximately half of type 2 diabetic patients achieve glycemic control, and undesirable side-effects often hamper treatment in those treated with the medications. There is a need for novel treatment options that can help overcome these difficulties. Sodium glucose cotransporter 2 (SGLT2) inhibitors have recently been developed as a novel potential therapeutic option for the treatment of type 2 diabetes. These drugs lower the plasma glucose concentration through inhibition of glucose reuptake in the kidney, independent of insulin secretion and insulin action, with a consequent lower risk of hypoglycemia. The data of clinical trials with monotherapy as well as combination therapy show that SGLT2 inhibitors have a blood glucose-lowering effect and also reduce bodyweight. A follow-up study shows long-term efficacy and the durability of these effects. SGLT2 inhibitors have the potential to reverse glucose toxicity, and to improve insulin resistance, blood pressure and lipid profile. The available data suggest a good tolerability profile. However, clinicians should carefully prescribe these drugs in light of already reported and/or unexpected side-effects. Further studies in larger numbers and longer-term clinical use data are required to place these agents in standard treatment of type 2 diabetes.

endocrinology & metabolism
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?

Munteanu Madalina Andreea,Swarnkar Surabhi,Popescu Razvan-Ionut,Ciobotaru Lucia,Nicolae Camelia,Tufanoiu Emil,Nanea Ioan Tiberiu

DOI: https://doi.org/10.3390/medicina59040742

2023-04-10

Abstract:There is a need for innovative pharmaceutical intervention in light of the increasing prevalence of metabolic disease and cardiovascular disease. The kidneys' sodium-glucose cotransporter 2 inhibitors (SGLT2) receptors are targeted to reduce glucose reabsorption by SGLT2. Patients with type 2 diabetes mellitus (T2DM) benefit the most from reduced blood glucose levels, although this is just one of the numerous physiological consequences. To establish existing understanding and possible advantages and risks for SGLT2 inhibitors in clinical practice, this article will explore the influence of SGLT2 inhibitors on six major organ systems. In addition, this literature review will discuss the benefits and potential drawbacks of SGLT2 inhibitors on various organ systems and their potential application in therapeutic settings.
Cervical mucus granulocyte macrophage colony stimulating factor and interleukin-2 soluble receptor in women using copper intrauterine contraceptive devices.

A. Shobokshi,M. Shaarawy

DOI: https://doi.org/10.1016/S0010-7824(02)00331-1

IF: 3.051

2002-08-01

Contraception

Abstract:
Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes Mellitus

Natasha Srinivas,Mubashira K Sarnaik,Srimy Modi,Yasaswi Pisipati,Sarayoo Vaidya,Naqvi Syed Gaggatur,Aliya H Sange,Ibrahim Sange

DOI: https://doi.org/10.7759/cureus.16868

2021-08-04

Cureus

Abstract:Diabetes mellitus is a leading cause of morbidity and mortality and a significant risk factor for the early onset of chronic kidney disease and heart disease. Hyperglycemia and insulin resistance are key factors that play a role in the pathogenesis of type 2 diabetes. Renal glucose reabsorption is a critical component of glycemic regulation. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, commonly known as gliflozins, lower blood sugar levels by inhibiting glucose absorption in the proximal tubule of the kidney. SGLT2 inhibitors are currently used primarily as antidiabetic medications; however, their advantages go well beyond just glycemic control. This article has reviewed the mechanisms behind cardiac and renal involvement in type 2 diabetes and their inseparable interconnections. This article has also discussed the pharmacokinetic and pharmacodynamic profile of different SGLT2 inhibitors available in the market. Finally, this review has provided a perspective on the outcome trials, which provide evidence supporting a potential benefit of SGLT2 inhibitors in reducing cardiovascular and renal risks and possible mechanisms that mediate the renal and cardiovascular protection conferred.
Nanomaterials Drug Delivery System in Herbal Formulation For Antidiabetic Activity: A Review

Raj Kumar Bera,Tripti Pal,Nilanjana Ghosh,Avery Kundu,Rajesh Ghosh,Kotupalli Srivalli,Kush Biswas

DOI: https://doi.org/10.15379/ijmst.v10i5.3635

2023-10-20

International Journal of Membrane Science and Technology

Abstract:Diabetes, a chronic metabolic disorder, results in high blood glucose levels due to insufficient insulin production or ineffective insulin utilization. Management entails lifestyle changes, exercise, and medication adherence. Monitoring blood sugar levels, healthy eating, and medication are crucial for controlling diabetes and preventing complications. The illness, currently incurable, necessitates management strategies for regulation. Medical treatments are expensive and require long-term adherence, leading many, especially those from low-income nations, to resort to herbal remedies. However, phytocompounds, though promising, often suffer from limited bioavailability due to poor solubility, permeability, or rapid elimination. Plant nanomedicines offer a promising avenue to address these challenges and alleviate the financial strain on disadvantaged populations. Encapsulated treatments using plant extracts or antidiabetic chemicals at the nanoscale have shown promising results. Our study aims to provide a thorough examination of lipid- and inorganic-based nanoparticulate delivery systems combined with plant extracts or phytocompounds for diabetes management Our analysis will highlight both the advantages and limitations of these systems for future clinical application. Examined studies revealed that nanoparticulate formulations displayed strong antidiabetic effects at lower doses compared to individual plant extracts or phytocompounds. Additionally, nanoparticulate systems have effectively addressed the issue of low bioavailability in herbal medications, showing promise for enhanced therapeutic outcomes.
Impact of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors on Atherosclerosis: from Pharmacology to Pre-Clinical and Clinical Therapeutics

Zhenghong Liu,Xiaoxuan Ma,Iqra Ilyas,Xueying Zheng,Sihui Luo,Peter J Little,Danielle Kamato,Amirhossein Sahebkar,Weiming Wu,Jianping Weng,Suowen Xu

DOI: https://doi.org/10.7150/thno.54498

IF: 11.6

2021-01-01

Theranostics

Abstract:Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are new oral drugs for the therapy of patients with type 2 diabetes mellitus (T2DM).Research in the past decade has shown that drugs of the SGLT2i class, such as empagliflozin, canagliflozin, and dapagliflozin, have pleiotropic effects in preventing cardiovascular diseases beyond their favorable impact on hyperglycemia.Of clinical relevance, recent landmark cardiovascular outcome trials have demonstrated that SGLT2i reduce major adverse cardiovascular events, hospitalization for heart failure, and cardiovascular death in T2DM patients with/without cardiovascular diseases (including atherosclerotic cardiovascular diseases and various types of heart failure).The major pharmacological action of SGLT2i is through inhibiting glucose re-absorption in the kidney and thus promoting glucose excretion.Studies in experimental models of atherosclerosis have shown that SGLT2i ameliorate the progression of atherosclerosis by mechanisms including inhibition of vascular inflammation, reduction in oxidative stress, reversing endothelial dysfunction, reducing foam cell formation and preventing platelet activation.Here, we summarize the anti-atherosclerotic actions and mechanisms of action of SGLT2i, with an aim to emphasize the clinical utility of this class of agents in preventing the insidious cardiovascular complications accompanying diabetes.
Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds

Xin Nie,Zhejie Chen,Lan Pang,Lin Wang,Huajuan Jiang,Yi Chen,Zhen Zhang,Chaomei Fu,Bo Ren,Jinming Zhang

DOI: https://doi.org/10.2147/ijn.s285134

IF: 7.033

2020-12-16

International Journal of Nanomedicine

Abstract:Xin Nie, 1 Zhejie Chen, 2 Lan Pang, 1 Lin Wang, 1 Huajuan Jiang, 1 Yi Chen, 1 Zhen Zhang, 1 Chaomei Fu, 1 Bo Ren, 1 Jinming Zhang 1 1 College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, People's Republic of China; 2 State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, 999087, People's Republic of China Correspondence: Jinming Zhang; Bo Ren Email cdutcmzjm@126.com; renbo@cdutcm.edu.cn In view of the worldwide serious health threat of type 2 diabetes mellitus (T2DM), natural sources of chemotherapies have been corroborated as the promising alternatives, with the excellent antidiabetic activities, bio-safety, and more cost-effective properties. However, their clinical application is somewhat limited, because of the poor solubility, instability in the gastrointestinal tract (GIT), low bioavailability, and so on. Nowadays, to develop nanoscaled systems has become a prominent strategy to improve the drug delivery of phytochemicals. In this review, we primarily summarized the intervention mechanisms of phytocompounds against T2DM and presented the recent advances in various nanosystems of antidiabetic phytocompounds. Selected nanosystems were grouped depending on their classification and structures, including polymeric NPs, lipid-based nanosystems, vesicular systems, inorganic nanocarriers, and so on. Based on this review, the state-of-the-art nanosystems for phytocompounds in T2DM treatment have been presented, suggesting the preponderance and potential of nanotechnologies. Keywords: type 2 diabetes mellitus (T2DM), phytocompounds, drug delivery systems, nanoparticles (NPs), antidiabetic effects

pharmacology & pharmacy,nanoscience & nanotechnology
Nanomaterial-enabled drug transport systems: a comprehensive exploration of current developments and future avenues in therapeutic delivery

Shatabdi Basu,Pragnya Biswas,Mariya Anto,Nandini Singh,Koel Mukherjee

DOI: https://doi.org/10.1007/s13205-024-04135-y

IF: 2.893

2024-11-06

3 Biotech

Abstract:Over the years, nanotechnology has gained popularity as a viable solution to address gene and drug delivery challenges over conventional methods. Extensive research has been conducted on nanosystems that consist of organic/inorganic materials, drugs, and its biocompatibility become the primary goal of improving drug delivery. Various surface modification methods help focus targeted and controlled drug release, further enabling multidrug delivery also. This newer technology ensures the stability of drugs that can unravel the mechanisms involved in cellular processes of disease development and its management. Tailored medication delivery provides benefits such as therapy, controlled release, and reduced adverse effects, which are especially important for controlling illnesses like cancer. However, multifunctional nanocarriers that possess high viscoelasticity, extended circulation half-life, biocompatibility, and biodegradability face some challenges and limitations too in human bodies. To produce a consistent therapeutic platform based on complex three-dimensional nanoparticles, careful design and engineering, thorough orthogonal analysis methods, and reproducible scale-up and manufacturing processes will be required in the future. Safety and effectiveness of nano-based drug delivery should be thoroughly investigated in preclinical and clinical trials, especially when considering biodistribution, targeting specific areas, and potential immunological toxicities. Overall, the current review article explores the advancements in nanotechnology, specific to nanomaterial-enabled drug delivery systems, carrier fabrication techniques and modifications, disease management, clinical research, applications, limitations, and future challenges. The work portrays how nanomedicine distribution affects healthcare with an emphasis on the developments in drug delivery techniques.

biotechnology & applied microbiology
Applications of SGLT2 inhibitors beyond glycaemic control

Daniel V. O’Hara,Carolyn S. P. Lam,John J. V. McMurray,Tae Won Yi,Samantha Hocking,Jessica Dawson,Smriti Raichand,Andrzej S. Januszewski,Meg J. Jardine

DOI: https://doi.org/10.1038/s41581-024-00836-y

IF: 42.439

2024-04-27

Nature Reviews Nephrology

Abstract:Sodium–glucose cotransporter 2 (SGLT2) inhibitors were initially developed for their glucose-lowering effects and have shown a modest glycaemic benefit in people with type 2 diabetes mellitus (T2DM). In the past decade, a series of large, robust clinical trials of these therapies have demonstrated striking beneficial effects for various care goals, transforming the chronic disease therapeutic landscape. Cardiovascular safety studies in people with T2DM demonstrated that SGLT2 inhibitors reduce cardiovascular death and hospitalization for heart failure. Subsequent trials in participants with heart failure with reduced or preserved left ventricular ejection fraction demonstrated that SGLT2 inhibitors have beneficial effects on heart failure outcomes. In dedicated kidney outcome studies, SGLT2 inhibitors reduced the incidence of kidney failure among participants with or without diabetes. Post hoc analyses have suggested a range of other benefits of these drugs in conditions as diverse as metabolic dysfunction-associated steatotic liver disease, kidney stone prevention and anaemia. SGLT2 inhibitors have a generally favourable adverse effect profile, although patient selection and medication counselling remain important. Concerted efforts are needed to better integrate these agents into routine care and support long-term medication adherence to close the gap between clinical trial outcomes and those achieved in the real world.

urology & nephrology
Prevention of Protein Glycation by Nanoparticles: Potential Applications in T2DM and Associated Neurodegenerative Diseases

Nayana Patil,Anushka Kelkar,Aruna Sivaram

DOI: https://doi.org/10.1007/s12668-022-00954-6

2022-02-18

BioNanoScience

Abstract:Glycation is the non-enzymatic covalent attachment of a sugar (carbohydrate) to a protein or lipid molecule. This process leads to the formation of advanced glycation end products (AGEs) which bind to the receptor for AGEs (RAGE) and facilitate further disease progression. Understanding the mechanisms for AGE formation in the progression of type 2 diabetes mellitus (T2DM) and neurodegenerative diseases can help target pathways that either facilitate AGE formation or the pathways that upregulate RAGE expression and activation. Several researchers have embarked on targeting these pathways either directly or indirectly. Nanoparticle (NP)–based approaches prove to be advantageous due to their modifiable surface properties, high biocompatibility and bioavailability in the body, minimal side effects and efficient blood–brain barrier permeability. Various drugs or therapeutic components can be encapsulated within them for targeted drug delivery. NPs explored in this study significantly brought down the overall reactive oxygen species (ROS) production, inhibited glycation and further fibrillation of particular proteins and increased cell viability. In this review, we discuss NPs that have shown a significant antiglycation property, ROS scavenging activity and blood–brain barrier permeability along with an ability to inhibit secondary structure changes and aggregation of proteins. However, clinical utility of these NPs still remains unclear as there is no clinical evidence to show that targeting of glycation with NP-based drug delivery systems could be a therapy for T2DM and reduce the risk of associated neurodegenerative diseases. Extensive research related to NPs with antiglycation properties may be a very successful approach for the treatment of T2DM and associated neurodegenerative disorders like Alzheimer’s disease.
PRospective Imaging of CErvical cancer and neoadjuvant treatment (PRICE) study: role of ultrasound to assess residual tumor in locally advanced cervical cancer patients undergoing chemoradiation and radical surgery

A. Testa,F. Moro,T. Pasciuto,M. Moruzzi,A. Legge,Gilda Fuoco,R. Autorino,A. Collarino,B. Gui,Gianfranco Zannoni,A. Gambacorta,M. Miccò,Vittoria Rufini,G. Scambia,G. Ferrandina

DOI: https://doi.org/10.1002/uog.18953

2018-05-01

Ultrasound in Obstetrics and Gynecology

Abstract:To determine the diagnostic performance of two‐dimensional (2D) ultrasound parameters, three‐dimensional (3D) power Doppler and contrast‐enhanced indices in detecting residual disease in locally advanced cervical cancer patients triaged to neoadjuvant treatment followed by radical surgery.
Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus

Panai Song,Akira Onishi,Hermann Koepsell,Volker Vallon

DOI: https://doi.org/10.1517/14728222.2016.1168808

IF: 6.797

2016-04-12

Expert Opinion on Therapeutic Targets

Abstract:INTRODUCTION: Glycemic control is important in diabetes mellitus to minimize the progression of the disease and the risk of potentially devastating complications. Inhibition of the sodium-glucose cotransporter SGLT2 induces glucosuria and has been established as a new anti-hyperglycemic strategy. SGLT1 plays a distinct and complementing role to SGLT2 in glucose homeostasis and, therefore, SGLT1 inhibition may also have therapeutic potential.AREAS COVERED: This review focuses on the physiology of SGLT1 in the small intestine and kidney and its pathophysiological role in diabetes. The therapeutic potential of SGLT1 inhibition, alone as well as in combination with SGLT2 inhibition, for anti-hyperglycemic therapy are discussed. Additionally, this review considers the effects on other SGLT1-expressing organs like the heart.EXPERT OPINION: SGLT1 inhibition improves glucose homeostasis by reducing dietary glucose absorption in the intestine and by increasing the release of gastrointestinal incretins like glucagon-like peptide-1. SGLT1 inhibition has a small glucosuric effect in the normal kidney and this effect is increased in diabetes and during inhibition of SGLT2, which deliver more glucose to SGLT1 in late proximal tubule. In short-term studies, inhibition of SGLT1 and combined SGLT1/SGLT2 inhibition appeared to be safe. More data is needed on long-term safety and cardiovascular consequences of SGLT1 inhibition.

pharmacology & pharmacy

Editorial: IEEE Transactions on Human-Machine Systems: Year in Review for 2013

Progress in Sodium-glucose Co-transporter-2 Inhibitors: the New Target for Treatment of Type 2 Diabetes

SGLT2i: beyond the glucose-lowering effect

SGLT2 inhibitors for the treatment of diabetes: a patent review (2019-23)

Synthetic approaches and clinical application of small-molecule inhibitors of sodium-dependent glucose transporters 2 for the treatment of type 2 diabetes mellitus

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Nondiabetic Patients with Chronic Kidney Disease: A Review of Recent Evidence

Sodium-glucose Cotransporter Type 2 Inhibitors: A New Insight into the Molecular Mechanisms of Diabetic Nephropathy.

SGLT2-INHIBITORS: A NOVEL CLASS FOR THE TREATMENT OF TYPE 2 DIABETES INTRODUCTION OF SGLT2-INHIBITORS IN CLINICAL PRACTICE

An apprise on novel drug delivery systems for management of diabetes mellitus

Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?

Cervical mucus granulocyte macrophage colony stimulating factor and interleukin-2 soluble receptor in women using copper intrauterine contraceptive devices.

Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes Mellitus

Nanomaterials Drug Delivery System in Herbal Formulation For Antidiabetic Activity: A Review

Impact of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors on Atherosclerosis: from Pharmacology to Pre-Clinical and Clinical Therapeutics

Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds

Nanomaterial-enabled drug transport systems: a comprehensive exploration of current developments and future avenues in therapeutic delivery

Applications of SGLT2 inhibitors beyond glycaemic control

Prevention of Protein Glycation by Nanoparticles: Potential Applications in T2DM and Associated Neurodegenerative Diseases

PRospective Imaging of CErvical cancer and neoadjuvant treatment (PRICE) study: role of ultrasound to assess residual tumor in locally advanced cervical cancer patients undergoing chemoradiation and radical surgery

Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus